Login
Companies $SUPN
$28.83 +$0.00 (0.0%) After hours
Supernus, Inc. logo

Supernus, Inc.

supernus.com

What Do They Do?

Sells SUBLOCADE, a long-acting buprenorphine injection for opioid use disorder, for patients treated by healthcare providers and health systems. Also sells buprenorphine-based sublingual medicines for opioid use disorder.

How Do They Make Money?

Wholesalers, specialty pharmacies and specialty distributors buy the medicines; a sale is completed when the customer receives the product. Government programs and commercial insurers have separate pricing arrangements.

FY2025 revenue

Who Are Their Customers?

Wholesalers, specialty pharmacies and specialty distributors buy directly, then distribute medicines through insurance, government programs and pharmacies. Outside the U.S., products also move through wholesalers, hospitals, pharmacies and individuals.

Do Revenues Turn Into Profits?

Yes. It kept 17 cents of every revenue dollar as net income in FY2025, but spent more cash than it brought in: free cash flow was −$93M.

Operating income, FY2025
21% of revenue
▲ +589% vs FY2024 ($38M, 3%)
Net income, FY2025
17% of revenue
▲ +2900% vs FY2024 ($7M, 1%)
Free cash flow, FY2025
−8% of revenue
▼ Turned to a loss vs FY2024 ($7M, 1%)

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q3 FY2026, the three months to Sep 30, 2026
Revenue
▲ +13%
vs $314M in Q3 FY2025
Net income
▲ +226%
vs $42M in Q3 FY2025
  • Aug 3, 2026 Agreed to merge with Supernus in an all-stock transaction If completed, Supernus would become a wholly owned subsidiary and Indivior would be renamed Supernus, Inc.
  • Aug 3, 2026 Raised full-year 2026 financial guidance The revised revenue range is $1,295 million to $1,365 million.

Who Do They Compete With?

Competes with Camurus

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support